Displasia broncopulmonar. Luciana F. Estima-se que cerca de 3. A DBP foi descrita inicialmente em por Northway et al.
|Published (Last):||21 January 2012|
|PDF File Size:||9.73 Mb|
|ePub File Size:||7.73 Mb|
|Price:||Free* [*Free Regsitration Required]|
Displasia broncopulmonar. Luciana F. Estima-se que cerca de 3. A DBP foi descrita inicialmente em por Northway et al. Em , Pursey et al. Em , Bancalari et al. Em nosso meio, Cunha et al. Desenvolvimento pulmonar e DBP. Em casos mais graves, a hipoxemia pode estar acompanhada de hipercapnia. Entre outras medidas preventivas, destacam-se as seguintes:. O uso dos broncodilatadores orais deve ser evitado, pelo maior risco de efeitos colaterais.
A capacidade residual funcional tende a normalizar-se entre 12 e 24 meses de idade. Atualmente, considera-se que o atraso no crescimento relaciona-se mais com a prematuridade e baixo peso ao nascer do que com o fato de esses pacientes serem portadores de DBP Existe, portanto, um amplo campo para pesquisa nesse assunto.
Silva Filho LVF. J Pediatr Rio J. Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol. Hazinski TA. Bronchopulmonary dysplasia. In: Chernik, V, editor. Disorders of the respiratory tract in children. Philadelphia: WB Saunders; Pulmonary disease following respiratory therapy of hyaline-membrane disease. N Engl J Med. Pulmonary fibroplasia following prolonged artificial ventilation of the newborn infant. Can Med Assoc J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr.
Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Jobe AH, Bancalari E. Nievas FF, Chernick V. Bronchopulmonary dysplasia: an update for the pediatrician. Clin Pediatr. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials.
Lung injury in neonates: causes, strategies for prevention, and long-term consequences. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J. Lyon A. Chronic lung disease of prematurity. The role of intra-uterine infection. Eur J Pediatr. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants.
Cochrane Database Syst Rev. Vitamin A deficiency and severe bronchopulmonary dysplasia in very low birthweight infants. Am J Perinatol. The role of inflammation in the development of chronic lung disease in neonates.
Papoff P. Infection, neutrophils, and hematopoietic growth factors in the pathogenesis of neonatal chronic lung disease. Eber E, Zach MS. Paediatric origins of adult lung disease. Greenough A. Measuring respiratory outcome. Semin Neonatol. Primhak RA. Discharge and aftercare in chronic lung disease of the newborn. Acta Paediatr. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. Williams O, Greenough A. Post-natal corticosteroid use. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.
Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Cole CH. Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease. Expert Opin Investig Drugs. Jobe AH. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.
Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatrics. Postnatal glucocorticoid therapy for prevention of bronchopulmonary dysplasia: routes of administration compared.
Inhaled glucocorticoid therapy in infants at risk for neonatal chronic lung disease. J Asthma. What is it, and how do we avoid it? Prevention of bronchopulmonary dysplasia. Curr Opin Pediatr. Shah PS. Current perspectives on the prevention and management of chronic lung disease in preterm infants.
Paediatr Drugs. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Ho LY. Bronchopulmonary dysplasia and chronic lung disease of infancy: strategies for prevention and management. Ann Acad Med Singapore. Intravenous or enteral loop diuretics for preterm infants with or developing chronic lung disease. Aerosolized diuretics for preterm infants with or developing chronic lung disease.
Update in: Cochrane Database Syst Rev. Ng GY, Ohlsson A.
Bronchopulmonary Dysplasia: Incidence and Risk Factors